1086 Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC)

✍ Scribed by Van Cutsem, E.; Gascón Vilaplana, P.; Seitz, J.F.; Van Laethem, J.L.; Grossi, F.; Bianco, A.R.; Dueland, S.; Bets, D.; Mueser, M.

• Book ID: 122033571
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 159 KB
• Volume: 1
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(03)91112-8